Ocular Surface Disease Treatments in the Pipeline

Potential treatments address inflammation and tear production, offer alternative mechanisms of action, or address a subset of dry eye.

1

The prevalence of dry eye disease (DED) exceeds 20 million in the U.S. and 350 million globally, highlighting its significant impact.
2

Recent advancements in ocular surface disease (OSD) treatments include novel mechanisms targeting inflammation and tear production.
3

Bausch + Lomb's Miebo and Tarsus Pharmaceutical's Xdemvy represent innovative approaches to treating evaporative eye disease and Demodex blepharitis.
4

Emerging therapies, such as AbbVie's reproxalap and Alcon's AR-15512, focus on novel inflammatory pathways and improved patient compliance.
5

The future of OSD treatment promises targeted therapies and enhanced diagnostics, aiming to improve outcomes for millions suffering from chronic conditions.

1